Aim To examine whether preoperative tumour size may serve as a biomarker for the occurrence of lymphovascular invasion (LVI) in centrally and peripherally located lung adenocarcinoma. Method The study included 261 patients surgically treated for diagnosed lung adenocarcinoma. A ROC curve was used to determine the biomarker potential of tumour size relative to the occurrence of LVI. Binary logistic regression was used to show changes of tumour size impact on the status of LVI. Result Tumour prevalence according to localization had no statistical significance (p=0.464), while the presence of LVI in central, as well as peripheral positions, was statistically significantly different (p<0.001). The area under the curve of 0.978 highlights the fact that tumour size is an excellent marker of the presence of LVI in centrally located adenocarcinomas of the lung. A similar finding was confirmed in peripherally located lung adenocarcinomas with an area below the curve of 0.943. Binary logistical regression showed that in centrally localized adenocarcinomas of the lung, each additional centimetre of tumour growth represents an increase in the likelihood of LVI+ by 17.14 times. In peripherally located adenocarcinomas of the lung, this increase in likelihood of LVI for each centimetre of growth was 5.46 times. Conclusion With a high degree of sensitivity and specificity, preoperative tumour size may serve as an important biomarker and positive predictor of the presence of LVI in lung adenocarcinoma of any location.
Mollberg N, Bennette C, Howell E, Backhus L, Devine B, Ferguson M. Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014;965–71.
2.
Sung S, Kwak Y, Lee S, Jo I, Park J, Kim K, et al. Lymphovascular invasion increases the risk of nodal and distant recurrence in node-negative stage I-IIA non-small-cell lung cancer. Oncology. 2018;156–62.
3.
Okiror L, Harling L, Toufektzian L, King J, Routledge T, Harrison-Phipps K, et al. Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018;785–93.
4.
Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, et al. The ratio of cancer cells to stroma within the invasive area is a histologic prognostic parameter of lung adenocarcinoma. Lung Cancer. 2018;30–5.
5.
Russell P, Wainer Z, Wright G, Daniels M, Conron M, Williams R. Does Lung Adenocarcinoma subtype predict patient survival? J Thorac Oncol. 2011;1496–504.
6.
Cancer Facts & Figures. 2018;
7.
Lin Y, Shidan W, David G, Yaniun Z, Feng X, Yuiwei L, et al. Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma; A large cohort analysis. Lung Cancer. 2018;22–6.
8.
Popper H. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;75–9.
9.
Riihimäki M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Clinical landscape of cancer metastases. Cancer Med. 2018;5534–42.
10.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Nicholson E, et al. The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;39–51.
11.
Wang S, Zhang B, Qian J, Qiao R, Xu J, Zhang L, et al. Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer. Lung Cancer. 2018;245–52.
12.
Chanyeong P, In J, Seung H, Jae. Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence. J Thorac Dis. 2014;1420–8.
13.
Grbic K, Mehic B. Characteristics of lymphovascular metastatic spread in lung adenocarcinoma according to the primary cancer location. Med Glas (Zenica). 2020;66–72.
14.
Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M, et al. The 2015 World Health Organization Classification of lung tumors impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;1243–60.
15.
Funai K, Sugimura H, Morita T, Shundo Y, Shimizu K, Shiiya N. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol. 2011;2968–72.
16.
Yang F, Chen K, Liao J, Li X, Sun K, Bao D, et al. Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma: a clinicopathologic study of 177 patients. World J Surg Oncol. 2014;285.
17.
Norifumi T, Takahiro M, Yoshihiro M, Shinsuke S, Tomoharu Y, Kei K, et al. Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma. Jpn J Clin Oncol. 2016;1015–21.
18.
Moon J, Lee K, Y, Jae S, K. Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. J Thorac Dis. 2016;169–77.
19.
Sun W, Yang X, Liu Y, Yuan Y, Lin D. Primary tumor location is a useful predictor for lymph node metastasis and prognosis in lung adenocarcinoma. Clin Lung Cancer. 2017;49–55.
20.
Yang L, Wang S, Gerber D, Zhou Y, Xu F, Liu J, et al. Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma; a large cohort analysis. Lung Cancer. 2018;22–6.
21.
Igai H, Matsuura N, Tarumi S, Chang S, Misaki N, Go T, et al. Prognostic factors in patients after lobectomy for p-T1aN0M0 adenocarcinoma. Eur J Cardiothorac Surg. 2012;603–6.
22.
Higgins K, Chino J, Ready N, ’amico D, Berry T, Sporn M, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol. 2012;1141–7.
23.
Hyun J, Hai X, Chang-Min C, Joon S, Hyeong R, Jung B, et al. Preoperative CT predicting recurrence of surgically resected adenocarcinoma of the lung. Medicine (Baltimore). 2016;(2):2513.
24.
Moulla Y, Gradistinac T, Wittekind C, Eichfeld U, Gockel I, Dietrich A. Predictive risk factors for lymph node metastasis in patients with resected non-small cell lung cancer: a case control study. J Cardiothorac Surg. 2019;11.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
